Rapid Screening for Elemental Impurities using ICP-MS

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-11-15-2014
Volume 2014 eBook
Issue 3

The authors describe a rapid, single-point calibration approach for ICP–MS analysis of raw materials used in drug product manufacturing.

 

The official implementation of United States Pharmacopeia (USP) <232> will require measurement of elemental impurities using inductively coupled plasma–mass spectrometry (ICP–MS). The authors describe a rapid, single-point calibration approach for ICP–MS analysis of raw materials used in drug product manufacturing.

 

Download Pharmaceutical Technology’s

2014 Analytical and Bioanalytical Testing eBook

.



 

Articles in this issue
PTebook1114_Viral_185.jpg
The Challenge of Finding the Unknown
PTebook1114_MethodTransfer_185.jpg
Keys to Successful Method Transfer
PTebook1114__AQbD185.jpg
AQbD Adds Rigor to Method Development
PTebook1114_SGS_185.jpg
Validation of a Multiplex Bead-Based Assay
PTebook1114_PerkinElmer_185.jpg
Rapid Screening for Elemental Impurities using ICP-MS
PTebook1114_Allotrope_185.jpg
Standardizing Data Management
PTebook1114_0Products.jpg
Advances in Analytical Technology
Recent Videos
Drug Digest: Strategic Partnerships
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Beckman Coulter Life Sciences Launches Modular Spectral Flow Cytometry Module, First of Its Kind in Industry

Feliza Mirasol
March 28th 2025
Article

The CytoFLEX mosaic Spectral Detection Module offers up to 88 channels for detection.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Issues Warning Letter to Aspen Biopharma Labs for API Manufacturing Deviations

Feliza Mirasol
March 27th 2025
Article

In the latest of a series of warning letters to India-based API manufacturers, FDA issued a warning letter to Aspen for deviations in CGMP in the production of APIs.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Novartis’ Steady Investments in Slovenia Result in New Viral Vector Manufacturing Facility and a Growing Work Force

Feliza Mirasol
March 27th 2025
Article

With a completed €40 million (US$43 million) investment in Slovenia, Novartis has opened its first specialized viral vector production facility in Europe, following earlier significant investments in R&D that has led to the growth of Slovenia’s workforce.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Benuvia Awarded NIH Contract for GMP Synthesis of Psilocybin, Other Drug Substances

Patrick Lavery
March 25th 2025
Article

The contract will support R&D of high-quality APIs for substance use disorders and mental health conditions, starting with synthesis and scale-up of psilocybin, which is derived from mushrooms.